Clinton's Science Adviser Faces Array Of Challenges

During 13 years as director of the Office of Technology Assessment, the job of John H. Gibbons--President Bill Clinton's choice as White House science adviser--was largely a balancing act. He had to provide Congress with independent, authoritative analysis of technical and scientific questions while treading gingerly amid divergent political views, bureaucratic turf battles, and special-interest "stakeholders." Washington observers familiar with OTA's track record give Gibbons high marks for

Written byBarton Reppert
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

During 13 years as director of the Office of Technology Assessment, the job of John H. Gibbons--President Bill Clinton's choice as White House science adviser--was largely a balancing act. He had to provide Congress with independent, authoritative analysis of technical and scientific questions while treading gingerly amid divergent political views, bureaucratic turf battles, and special-interest "stakeholders."

Washington observers familiar with OTA's track record give Gibbons high marks for leading the agency through potential minefields--including nuclear power and other environmentally sensitive energy issues, Star Wars missile defense research, genetic engineering, electronic surveillance, and health care policy. In the face of controversy, OTA's role has been not to take sides, but instead to prepare comprehensive, dispassionate assessments of the available data, and then offer a balanced selection of possible policy options.

Characteristically, Gibbons's initial public remarks after being appointed by Clinton have also been carefully balanced.

"Our security and prosperity depend, as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies